News

Santé log40m
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
Within R&D, Novo Nordisk completed the REDEFINE 2 trial, where CagriSema demonstrated superior weight loss of 15.7% in adults with obesity or overweight and type 2 diabetes. Novo Nordisk still expects ...
Santé log40m
Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis
Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced positive results from its pivotal, phase 3 trial (NUC-5) on norucholic acid ...
Santé log40m
Yaqrit’s HE candidates set for phase 3 as company shows underpinning data at EASL
Improved disease staging tool for hepatic encephalopathy, approved for use by FDA in phase 3 trials of IV ammonia scavenger (YAQ006) Dose-response data of oral ammonia scavenger (YAQ007) for ...
Santé log40m
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
“These data show that the long-term efficacy, safety, and convenience profile of ALXN1840 are very encouraging and that ALXN1840 has the potential to provide a meaningful benefit to Wilson disease ...
Santé log40m
Valneva publie ses résultats financiers du premier trimestre 2025 et fait un point sur son activité
Valneva retransmettra aujourd’hui en direct la conférence téléphonique sur ses résultats financiers du premier trimestre 2025 à 15h00 CEST (9h00 EDT). Cette retransmission sera disponible sur le site ...